Oncology Malpractice Claims: When Cancer Treatment Goes Wrong

## Medical Malpractice in Cancer Care: A Growing Legal Category

As cancer treatment becomes more complex and specialized, the potential for oncology malpractice increases alongside it. Claims in this category span the full cancer care continuum: misdiagnosis or delayed diagnosis allowing cancer to advance, chemotherapy overdose or wrong-drug errors causing organ failure, radiation treatment targeting errors destroying healthy tissue, and failure to monitor for known toxicities of aggressive treatment protocols. These are high-value cases given the catastrophic nature of the harm and the high insurance coverage carried by oncology practices.

Chemotherapy dosing errors — including five-fold overdoses from unit confusion (mg/kg vs. mg/m²) — cause an estimated 1,000 serious injuries annually in U.S. cancer centers.

Categories of Oncology Errors That Support Malpractice Claims

Every stage of cancer care presents malpractice risks. At diagnosis, failure to biopsy a suspicious lesion, delays in referring to an oncologist, or misreading a pathology specimen can allow cancer to advance from a curable to an incurable stage. During treatment, chemotherapy is among the most dangerous class of medications administered in medicine — errors in protocol selection, dose calculation, or administration sequence can be fatal.

• Delayed or missed cancer diagnosis allowing progression to advanced stage
• Pathology misread: benign vs. malignant specimen error
• Chemotherapy overdose or wrong protocol selection
• Radiation therapy field errors destroying healthy organ tissue
• Failure to monitor for known cardiotoxicity or nephrotoxicity of treatments
• Failure to refer a high-risk patient for genetic testing and screening

The Causation Challenge in Oncology Malpractice

Oncology cases face a difficult causation question: would earlier or correct treatment have changed the outcome in a patient who may have died regardless? Your attorney's oncology expert must provide a specific, defensible opinion about how the outcome would have differed with proper care — expressed in statistical survival probability differences that juries can understand and apply. These cases require the best available oncological experts to overcome defense arguments about cancer's inherently unpredictable progression.